Sunway Healthcare Lists at RM16.7 Billion. Is the Premium Justified?

Sunway Healthcare lists on 18 March 2026 at a market capitalisation of RM16.7 billion.

It’s Malaysia’s largest IPO in nine years — raising RM2.86 billion, more than 99 Speed Mart’s RM2.36 billion in 2024, and the biggest fundraise on Bursa since Lotte Chemical Titan grossed RM3.77 billion in July 2017.

The Sunway brand is familiar. The hospital network is well-regarded. But at this price, the question is straightforward: are the numbers strong enough to justify the premium?

It’s Not Cheap

At RM1.45 per share, Sunway Healthcare is priced at 36.1x EV/EBITDA and 64.8x trailing PE. That’s well above both domestic and regional peers.

So why would investors pay up? One indicator: revenue per operating bed.

Sunway generates the highest revenue per bed among the three listed players. The difference comes down to case mix: Sunway focuses on higher-complexity procedures — robotics, transplants, quaternary care. Its flagship Sunway Medical Centre in Sunway City KL is one of the largest hospitals in Southeast Asia with 848 licensed beds.

Higher complexity means structurally higher margins. You’re paying for positioning at the top end of the value chain.

Growth Is the Real Story

Between 2022 and 2024, revenue nearly doubled — from approximately RM1.0 billion to RM1.85 billion. Net profit rose 42% in 2024 alone, reaching RM257.5 million.

EBITDA growth was even stronger, outpacing many listed hospital peers. This isn’t incremental expansion. It’s scale with operating leverage.

The market is pricing Sunway as a platform, not just a hospital operator. The company plans to double its bed capacity to over 3,600 by 2032, funded partly by the RM833.8 million in primary proceeds from this IPO.

Industry Structure Matters

Despite large names like KPJ, IHH and Sunway, the Malaysian private healthcare market remains fragmented. Many independent operators. Regional players. Standalone hospitals.

That leaves room for consolidation. Strong brands with scale, specialist depth and capital access are structurally advantaged. The question isn’t whether consolidation happens. It’s who leads it.

Sunway currently operates 1,306 operating beds across four hospitals (1,396 licensed). IHH has over 3,500 beds in Malaysia. KPJ has over 3,700. Sunway is the smallest of the three listed players — but growing the fastest.

The Real Debate

Hospitals are capital intensive. High fixed costs. Expensive equipment. Specialists must be retained regardless of short-term fluctuations. Execution matters when scaling capacity.

The demand side isn’t the question. Malaysia is projected to become an aged nation by 2048, when citizens aged 65 and above will reach 14% of the total population, according to the Department of Statistics. The fertility rate has been below replacement level since 2013. Healthcare demand is structural.

The debate is valuation. At 36.1x EV/EBITDA — more than double what IHH and KPJ trade at — are you buying:

• A long-duration healthcare compounder with best-in-class positioning, or
• Growth that’s already priced in?

That’s what investors need to decide before 18 March.

Key IPO Details

How We Found This

All financial data comes from Sunway Healthcare’s IPO prospectus dated 27 February 2026 and public filings on Bursa Malaysia. Peer valuation multiples are trailing figures at time of writing. The aging population projection is from the Department of Statistics Malaysia, as cited by the Finance Ministry.

Want to stay on top of Bursa filings and market moves? Try Sang Tikam on Telegram — AI-scored alerts for the announcements that actually matter.